Posts

Meet Dr. Sandra Bosold

News from IFAPP Academy

Get to know the students of the IFAPP Academy!

The IFAPP Academy is proud to highlight the achievements and successes of our current students and alumni.

We would like to introduce you to, Dr. Sandra Bosold, a current student of the IFAPP Academy/King’s College London, Medical Affairs in Medicines Development, Certification Program.

IFAPP Academy featured student: Dr. Sandra Bosold

What is your name and job title?

Dr. Sandra Bosold, Scientific Advisor PIH

What do you feel is your greatest achievement?

One daily achievement is to manage my job responsibilities and the activities and needs of my family. Due to the flexibility of my employer and the appropriate infrastructure, it is possible to balance both.

What is your favorite hobby and/or activity outside of your work?

Gardening and family.

What do you enjoy most about being a Medical Affairs Professional?

Working as a MAP you are at the interface between the medical/scientific world and the interests of a company. Scientific exchanges with HCPs, participation in conferences, and discussions with patients are at the center of our activities and make this job incredibly interesting.

What has been the most beneficial aspect of the IFAPP Academy Program?

Besides the well-structured and detailed lectures, the live webinars with the opportunity to discuss certain issues with top experts but also with the IFAPP colleagues are extremely valuable.

How has your view of the medical affairs profession altered and/or improved?

While going through the curriculum it became clear that Medical Affairs is at the center of all activities and cannot be underestimated. The discussions with KOLs, the insights into patients’ journeys, the scientific knowledge and the cooperation with academia are the foundation of our business.

Any additional comments that you would like to make about the Program?

I have greatly benefitted from the exchange with colleagues from all over the world. IFAPP’s program is a truly global one.

Thank you, Sandra! The Academy looks forward to seeing your many great achievements and contributions to the Medical Affairs arena.

Want to learn more about the IFAPP Academy?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Applications are now being accepted for the 2019 Cohort. Click here for more information. Application deadline is December 1st, 2018.

Get to know the students of the IFAPP Academy



News from IFAPP Academy


Get to know the students of the IFAPP Academy!

Meet Maribel Tribaldos, Medical Head Vaccines at Sanofi Pasteur Pacific and Caribbean

The IFAPP Academy is proud to provide continuing professional development to Medical Affairs Professionals worldwide. This month, we would like to introduce you to, Maribel Tribaldos, a current student of the IFAPP Academy/King’s College, Medical Affairs in Medicines Development, Certification Program.

IFAPP Academy Feature Student: Maribel Tribaldos

What is your name and job title? Maribel Tribaldos, Medical Head Vaccines Sanofi Pasteur Pacific and Caribbean

What do you feel is your greatest achievement? From the professional standpoint, my greatest achievement has been to rapidly progress in my career while maintaining a work and personal life balance.

What is your favorite hobby and/or activity outside of your work? Reading and spending time with my family

What do you enjoy most about being a Medical Affairs Professional? The need of constant training and the strategic thinking needed for each product.

What has been the most beneficial aspect of the IFAPP Academy Program? Acquiring a knowledge that is very valuable for the job but is not easily available in the standard trainings.

How has your view of the medical affairs profession altered and/or improved? My view of medical affairs has improved, from a narrow perspective of a simple job description to a position that plays a paramount role in the products life cycle.

Any additional comments that you would like to make about the Program? I encourage all medical affairs professionals to enroll in this wonderful journey that will enrich your knowledge and advance your career.

Thank you, Maribel! The Academy looks forward to your continued success in the medical affairs arena.

Want to learn more about the IFAPP Academy?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

Get to know the students of the IFAPP Academy!

News from IFAPP Academy


Get to know the students of the IFAPP Academy!

Meet Asmaa Salah Abdel Khalek, a Clinical Trial Evaluator and Auditor at the EDA, the Egyptian Drug Authority.

The IFAPP Academy is proud to provide continuing professional development to Medical Affairs Professionals worldwide. This month, we would like to introduce you to, Asmaa Salah Abdel Khalek, a current student of the IFAPP Academy/King’s College, Medical Affairs in Medicines Development, Certification Program.

Asmaa Salah Abdel Khalek, Clinical Trial Evaluator and Auditor, EDA

What is your name and job title?

I’m Asmaa Salah Abdel Khalek, Clinical Trial evaluator and auditor at the EDA, the Egyptian Drug Authority.

What do you feel is your greatest achievement?

My greatest achievement could be simplified in my dream to improve the clinical trial regulation in my country, to cope with the international guidelines.

Currently, I’m working in the national NRA and due to my continuous search and education in the clinical research field, I can see a lot of obvious gaps in the regulations of the clinical trials in my country. I truly hope to be one of the team that will standardize and unify the clinical trial regulations which will have a great impact on the provided pharmaceutical services across all the different healthcare sectors. You start to improve the moment you figure out the weak points and work on them.

What is your favorite hobby and/or activity outside of your work?

My favorite hobby is walking in an open area, listening to my favorite music.

What do you enjoy most about being a Medical Affairs Professional?

First, it was a great honor for me to hear about the medical affairs professional degree provided by IFAPP. I’m totally interested in this specialty which is now the direction of all the huge pharmaceutical companies.  Working in a patient-centered approach, integrating the medical affairs specialists as key members along the entire product lifecycle.  Through a mutual collaboration with all the company staff, starting from studying the market to detecting the medical needs, aiming to meet these needs, then helping the academic scientists to deliver their basic research and input, to shift from bench to lab, and then the huge massive clinical trial initiation, and monitoring, regulatory approval and marketing authorization, marketing plan starting from studying the market, targeting the main stakeholder, positioning etc.…. followed by the post-marketing and outcome research studies that may help to support the product value. Medical affairs is a broad concept, it could be an MSL, CRA, marketing team, regulatory affairs and so much more.

This is a new direction with a great impact, improving the performance. And for me, I’m completely interested in the clinical research sections and regulation pre and post-marketing authorization.

What has been the most beneficial aspect of the IFAPP Academy Program?

The most beneficial aspect of the IFAPP Academy Program is its professional organization which truly helped me to make a complete picture of the medical affairs profession.  Also, the lecturers, listening to these lectures from professional professors who already have a great experience and are completely updated in that field was very helpful. Lastly, the rich content and the flexibility of the program.

How has your view of the medical affairs profession altered and/or improved?

The medical affairs profession altered to be patient-centered and improved to make a great progress across all the product lifecycle, integrating with all other sectors in the company.

Any additional comments that you would like to make about the IFAPP Academy/King’s College, Medical Affairs in Medicines Development, Certification Program?

I would like to say thank you to all the IFAPP team and the program director for their patience and the great support they presented to us in this great program.

Thank you, Asmaa! The Academy looks forward to seeing your many great achievements and contributions to the Medical Affairs arena.

Want to learn more about the IFAPP Academy?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

Get to know the students of the IFAPP Academy!

News from IFAPP Academy


Get to know the students of the IFAPP Academy!

Each month the IFAPP Academy will highlight the achievements and successes of a current student or alumnus.


The IFAPP Academy is proud to provide continuing professional development to Medical Affairs Professionals worldwide. To showcase our students and their achievements, the Academy is starting a new feature where we will highlight a current student or an alumnus of the IFAPP Academy each month.

This month, we would like to introduce you to, Olena Kurayeva, a current student of the IFAPP Academy/King’s College, Medical Affairs in Medicines Development, Certification Program.

Featured IFAPP Academy Student: Olena Kurayeva

What is your name and job title?

Olena Kurayeva, Western Belt PEH Medical Lead in Pfizer

What do you feel is your greatest achievement?

Being Pfizer Medical Lead, with close collaboration with National key decision makers to get the process of National antimicrobial stewardship program creation initiated

What is your favorite hobby and/or activity outside of your work?

Family, Reading, Jogging. I enjoy being with my husband and our daughter. This is where I charge my batteries and fuel my professional life.

What do you enjoy most about being a Medical Affairs Professional?

“Working as a physician in a premier innovative biopharmaceutical company in the upcoming era of Big Data medicine puts me in a unique position to link scientific and clinical results to patient outcomes.”

What has been the most beneficial aspect of the IFAPP Academy Program?

Flexible schedule-opportunity to study in the most convenient time and place, mature experts in different areas and nice delivery.

How has your view of the medical affairs profession altered and/or improved?

This program helped to identify more areas where I can make a difference as a Medical Lead, which results in bringing additional value to the company, and where my background is essential.

Any additional comments that you would like to make about the IFAPP Academy/King’s College, Medical Affairs in Medicines Development, Certification Program?

Thank you and keep going with the same spirit!

Thank you, Olena! The Academy looks forward to seeing your many great achievements and contributions to the Medical Affairs arena.

Want to learn more about the IFAPP Academy?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.


The IFAPP Academy’s Core Competencies are truly ‘the Core of Medical Affairs’

News from IFAPP Academy


The IFAPP Academy’s Core Competencies are truly ‘the Core of Medical Affairs’


Core Competencies of Medical Affairs

The IFAPP Academy/King’s College, Medical Affairs in Medicines Development, 2018 Cohort is finishing up Module 4 exams, starting this week. This means there are only 2 Modules remaining before the End of Program Assessment, to culminate in the Certification of this year’s qualifying students. Students successfully completing the program will be able to use the post-nominal letters CMD as a designation of their earned competencies.

The IFAPP Academy Core Competencies align with the McKinsey & Co report on the Core Capabilities of Medical Affairs Professionals.

MCKINSEY & CO CORE CAPABILITIES IN MEDICAL AFFAIRS
IFAPP STATEMENT OF COMPETENCE IN MEDICINES DEVELOPMENT
Scientific and technological leadership
and strategic vision
Can identify unmet therapeutic needs, evaluate the evidence for a new candidate for clinical development and design a Clinical Development Plan for a Target Product Profile.
Scientific and technological leadership
Can design, execute and evaluate exploratory and confirmatory clinical trials and prepare manuscripts or reports for publication and regulatory submissions.
Learning agility
Can interpret effectively the regulatory requirements for the clinical development of a new drug through the product life-cycle to ensure its appropriate therapeutic use and proper risk management.
Deep understanding of compliance
Can evaluate the choice, application, and analysis of post-authorization surveillance methods to meet the requirements of national/international agencies for proper information and risk minimization to patients and clinical trial subjects.
Strategic vision & scientific leadership
Can combine the principles of clinical research and business ethics for the conduct of clinical trials and commercial operations within the organization.
Deep understanding of compliance
Can appraise the pharmaceutical business activities in the healthcare environment to ensure that they remain appropriate, ethical and legal to keep the welfare of patients and subjects at the forefront of decision making in the promotion of medicines and design of clinical trials.
Emotional intelligence and communication skills
Emotional intelligence and communication skills

According to McKinsey & Co. (Evers, et al., 2014), “the bar is high for Medical Affairs talent. They need to collaborate with R&D colleagues and deeply understand the science that underpins their work; they must understand the rules and regulations governing the industry almost as well as their compliance and legal department colleagues; and they should have the strategic thinking capabilities of their marketing counterparts as well as the customer-interaction skills of their colleagues in sales.”

IFAPP Academy students gain the necessary knowledge and understanding to create patient-centric environments where they can interact with a broad range of stakeholders to provide a more tangible value to patients. This has become increasingly important as “the right talent is often scarce, especially at the local country level.” The IFAPP Academy is proud to help fill this gap by providing online Continuing Professional Development for Medical Affairs Professionals.

For more information and to apply for the 2019 IFAPP Academy/King’s College, Medical Affairs in Medicines Development Certification Program click here.

References

Evers, M., Edd, F., Ghatak, A., Hartmann, J., Westra, A., Nathoo, A., . . . Suresh, B. (2014, July). Pharma Medical Affairs: 2020 and beyond. Retrieved July 18th, 2018, from McKinsey & Co.: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/pharma-medical-affairs-2020-and-beyond#0

Check out these 5 key areas for CRO process improvement

Hot Topics in Medical Affairs


5 Key Areas for CRO Process Improvement

Insight into 5 key areas where CRO’s should consider ongoing process improvement.


An article from the May 2018 addition of the Clinical Researcher seems especially relevant as the students of the current 2018 cohort are wrapping up Module 4, Clinical Trials: from concept to clinical study report. The article “Improving Clinical Research Trials: Best Practice Do’s and Don’ts for Managing Business Operations” (Ted Finlan, 2018), Finlan provides insight into 5 key areas where CRO’s should consider ongoing process improvement.



1.      Regulatory Compliance

Pitfall: Failure to understand and plan compliance timelines

Internal and external regulatory groups have varying deadlines, with timelines that often intersect and overlap. For instance, approval for a drug import license can vary from country to country by a matter of weeks or months. Without a clear understanding of approval processes and their impact on the critical path, a study is at high risk of schedule slippage.

Best practice: Clear project planning blueprint

CROs should ensure clarity and alignment between staff responsible for designing a regulatory blueprint (e.g., ethics committees, institutional review boards, etc.) and those responsible for building, managing, and communicating schedules. When approval processes are clearly mapped out to achieve the most efficient response, CROs can expedite the commencement of work.

2.      Information Flow and Governance

Pitfall: Lack of communication between departments and across organizations

Every department maintains critical information that other departments can benefit from. For instance, the Quality unit may be the first to become aware of new clinical trial regulations that impact the study start-up processes. If this information is not shared across the organization, various issues may arise, such as compromised core processes and missed timelines, jeopardizing overall delivery of the study.

This risk can be especially acute when working with new partners or third parties. Misplaced assumptions about “who knows what” or misaligned processes can creep in and drive quality issues or delays if initial and ongoing communication between these entities is lacking.

Best practice: Purposeful communication and collaboration

Clarity is a best practice when it comes to communication, and standard operating procedures should address optimal information flow. This requires every team member and site to have a clear understanding of their own responsibilities, as well as the roles and responsibilities of those adjacent to them. Processes should lend to proactive knowledge sharing as departments recognize how information intersects and how teams can fully leverage intelligence.

Mutually agreed-upon terms of engagement between sponsors, CROs, and vendors can also circumvent downstream quality, compliance, or timeline issues. These communication plans should ensure collaboration across all facets of the project.

3.      Getting a Fast Start

Pitfall: Final protocol delays

Delayed availability of the final protocol is one of the most significant stumbling blocks to patient recruitment. The final protocol is a critical path deliverable that impacts trial supply, site activation, and, of course, recruitment.

In fact, quite often, important work will begin before the final protocol is available. Proceeding “at risk” can lead to rework that can increase the cost and duration of start-up, and, in some cases, could lead to losing access to desirable clinical investigators or institutions. All of which impacts the ability to recruit and can affect the pace of recruitment throughout the study.

Best practice: Transparency and communication

Visibility into the availability of the protocol and expected impacts can significantly mitigate the impacts of delays. By actively planning for the delays and communicating proactively with the sites, a CRO can maintain engagement and be far more agile in adapting to change. This requires proactive communication and strong collaboration between the sponsor and CRO to make the changes needed for strategies, systems, and plans to run as smoothly and quickly as possible.

4.      Budgeting

Pitfall: Improper management of uncertainty

A key characteristic of research is uncertainty. Unfortunately, that reality can make the budgeting process a series of “best guesses.” As noted above, delays in protocol availability can delay studies for unpredictable periods of time, as can the availability of investigational product (IP) supplies.

These, and other unknowns can lead to rework, changing of staff, and other impacts that affect the overall budget, including direct CRO services, grants, and third-party costs. Without effectively forecasting communication and change order processes, studies can run into financial trouble, including an inability to compensate investigators or pay third-party costs.

Best practice: Effective change management

In an ideal world, any CRO would like to minimize risk by matching the level of uncertainty with the right amount of “insurance,” often referred to as a reserve. This is rarely possible, yet the most effective CROs move forward with a considered, deliberate approach for “out of scope” work and a smooth change order process.

Another approach is to financially ensure alignment and motivation through targeted use of bonus clauses, incenting CRO performance by aligning its financial benefit with the goals of the sponsor. For example, hitting aggressive recruitment and retention targets.

It is important to remember that these approaches are two-way streets. Change orders for unused/unrequired spending result in savings for the sponsor and should be communicated just as proactively. As this may be driven by faster recruiting or other “good news,” it may appear to some that the CRO is being punished for exceptional performance. This is another good reason to align incentives and bonuses to match the sponsor’s desired outcomes.

5.      Staff Workflows

Pitfall: Finding projects short-staffed

Inefficiency is always a concern, and the ability to efficiently allocate staff is a critical factor for service companies. A lack of consistency across organizations, various conflicting or ambiguous definitions for terms and data, misaligned assumptions, and an absence of clarity across processes and organizations can leave projects short of key staff, driving delays, quality issues, and other delivery problems.

Best practice: Aligning key resources

A holistic view of processes and clear data definition across the enterprise is key. This is usually attacked by mapping and integrating core processes, and in the case of services staffing, this is often referred to as the “quote to cash” process. As it sounds, this process takes the proposal and bidding activities into consideration, where staff capacity transitions to the reservation of specific individuals.

Once the formal assignment is in place and resources are used, the process moves into the billing and receivables portion. By clearly illustrating the processes and agreeing to common data definitions and metrics, the CRO can gain greater visibility into its “factory” and more efficiently serve its customers.

To sum up, “Good Business Operations = Effective Trials.”  Finlan, emphasizes that as the clinical research environment continues to grow and change it becomes ever important to ensure a high-quality design to overcome these common pitfalls and ensure success!

Want to learn more about how to be an effective and more productive CRO?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

 

References:

  1. Ted Finlan, P. C. (2018, May 15). Improving Clinical Research Trials: Best Practice Do’s and Don’ts for Managing Business Operations. Clinical Researcher, 32(5). Retrieved July 7, 2018, from https://www.acrpnet.org/2018/05/15/improving-clinical-research-trials-best-practice-dos-donts-managing-business-operations/

3 Reasons why medical affairs professionals need to be savvy with social media

Hot Topics in Medical Affairs


3 Reasons why medical affairs professionals need to be savvy with social media.



The worldwide reach of social media has changed how people communicate. Social media platforms are becoming the go-to source for communication.  Patients are more likely to share their medication side effects, such as the itchy rash they got on their butt or the achy joints that prevented them from playing golf with friends, on social media than to their doctor. Social media channels not only have the potential to act as a way of reporting adverse events but also help companies understand the wants and needs of patients.

Therefore, with the ever-increasing importance of patient centricity and personalized medicines, more and more companies are relying on social media to provide them with answers. These are just some of the many ways that companies are leveraging social media.

1.  Creating a truly patient-centric approach

“There has been a lot of talk in recent years of a need to increase patient-centricity within the pharmaceutical industry. Indeed, there have been many great steps towards a more patient-centric approach, and a greater recognition of the value of patient choice and the need for increased self-management across healthcare systems” (Rees, Sumira, & Morton, 2018).  However, to put this into practice companies must provide patients with the necessary tools and education. Companies are now relying on data from social media sites to help them learn how to provide patient-friendly information.  “Listening to social conversation can add layers of insights. Online conversations can uncover valuable insights about the audience, whether this be patients, healthcare professionals or key opinion leaders.” (Rees, Sumira, & Morton, 2018)

[caption id="attachment_2000" align="aligncenter" width="845"] Figure 1 Sciformix Corp. “The Impact and Use of Social Media in Pharmacovigilance”

2. Product Vigilance (PV)

In a whitepaper by Sciformix, “social media has the potential to become an added new-age tool to monitor data in real-time, making it an early indicator of potential safety issues for further investigation. Further, this would enable companies to generate more robust product safety profiles by leveraging the additional social media information” (Sciformix Corporation).

3.  Clinical trial recruitment

According to Medrio.com, “Social media has the potential to be a powerful tool in the clinical trial recruitment process because of its low cost and ability to reach a diverse and broad audience. In 2014, Facebook boasted over 1.2 billion monthly active users, Twitter had 255 million, LinkedIn was at 187 million.  These numbers outweigh the traditional recruiting numbers in every way.  This capability is something that one-sided print/TV ads or even clinician/patient referrals cannot provide: access to diverse cultures, age groups, gender, and income levels” (Medrio, 2015).


Want to learn how to expand your skillset and continue your professional development in Medical Affairs?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.


 

References

Medrio. (2015, August 6). Using Social Media to Recruit Subjects in Phase I Clinical Trials. Retrieved from Medrio: https://medrio.com/blog/using-social-media-to-recruit-subjects-in-phase-i-clinical-trials/

Rees, N., Sumira, D., & Morton, A. (2018, June 13th). The Patient Journey. Retrieved June 19, 2018, from PM LiVE: http://www.pmlive.com/pharma_thought_leadership/the_patient_journey_1239641

Sciformix Corporation. (n.d.). The Impact and Use of Social Media in Pharmacovigilance. Retrieved June 19, 2018, from Sciformix: https://www.sciformix.com/wp-content/uploads/Social_Media_in_PV_Whitepaper.pdf

World Pharma News. (2017, October 9). Social Media in the Pharmaceutical Industry. (SMi Group) Retrieved June 6, 2018, from World Pharma News: http://www.worldpharmanews.com/events/4139-social-media-in-the-pharmaceutical-industry

What are the benefits of earning a professional certification?

Hot Topics in Medical Affairs


What are the benefits of earning a professional certification?

Despite the career, employees from construction to IT to Pharmacy have found enormous advantages in obtaining a professional certification within their field. Here are 5 advantages of earning professional certification.



  1. Gain a competitive edge. Because let’s face it, competition can be stiff when it comes to the job market. Whether you’re applying for a new job, wanting to be considered for a promotion, or crossing your fingers for an end-of-year raise a professional certification will help to distinguish you from the pack. When considering two individuals with similar backgrounds, a professional certification may get your resume that second look. Certifications can differentiate you from other professionals in your field or company, showing that you have a demonstrated commitment to understanding and excelling in your profession and a desire to learn more.[1]

2.  Increased competency. The success of a team depends on the knowledge and experience of each of its members, which is why professional certifications have become increasingly important in the field of medicine.[2] After all, the primary criteria for employers is to have professionals on their team that are up-to-date with industry standards, norms, and best practices which are in a constant state of flux.[3] E-learning allows providers, such as the IFAPP Academy, to provide the most current and relevant information in an accessible, convenient, and cost-effective manner.

3. Professional credibility. Earning a certification provides immediate credibility with employers and colleagues. Who is going to question a Cisco Certified Internetwork Expert (CCIE), a Microsoft Certified Solutions Expert (MCSE) or a Red Hat Certified Architect (RHCA)? Earning a certification from an internationally recognized organization demonstrates your dedication and motivation to professional development. Many companies will actively support their employees in earning these certifications that may even lead to promotions and raises.[4]

  1. Networking opportunities. Working hard to earn a certification allows you to join a unique group of certified and skilled professionals that share similar goals and ambitions. This can prove to be an invaluable peer resource group that can be a boon when looking for answers to a particularly tough problem or when moving from one company to another. The IFAPP Academy encourages students to network and learn from each other through the student forums and live interactive webinars, providing additional viewpoints from an international perspective.

5.  Increased confidence, because confidence is KEY! In a study conducted by the University of Melbourne, Participants were asked to describe their level of confidence at primary school, high school, university, and present day. Those who self-reported higher levels of confidence earlier in school earned better wages and were promoted more quickly.  Lead author Dr. Reza Hasmath, from the University’s School of Social and Political Sciences, said the research demonstrates a crucial ingredient of workplace advancement.  “The implications are tremendous in terms of the personality employers should look for when it comes to hiring or promoting staff,” Dr. Hasmath said.”[5]

Want to learn how to earn a Professional Certification in Medicines Development in Medical Affairs?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals, resulting in the Professional Certification, CMD (Certified Medicines Development).

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

Resources/References

[1] Laurinavicius, T. (2017, December 07). Why Online Certifications Are Key To Professional Success. Retrieved March 28, 2018, from https://www.huffingtonpost.com/tomas-laurinavicius/why-online-certifications_b_11081630.html

[2] Rewards of Certification. (n.d.). Retrieved March 28, 2018, from https://www.bpsweb.org/impact-of-bps-certification/rewards-of-certification/

[3] Laurinavicius, T. (2017, December 07). Why Online Certifications Are Key To Professional Success. Retrieved March 28, 2018, from https://www.huffingtonpost.com/tomas-laurinavicius/why-online-certifications_b_11081630.html

[4] 10 Benefits of IT Certification for You (and Your Employer). (n.d.). Retrieved March 28, 2018, from https://www.globalknowledge.com/us-en/content/articles/10-benefits-of-it-certification-for-you-and-your-employer/

[5] Hasmath, D. (2012, October 18). Self-confidence the secret to workplace advancement. Retrieved April 09, 2018, from http://newsroom.melbourne.edu/news/self-confidence-secret-workplace-advancement

The Changing Face of Medical Affairs

Hot Topics in Medical Affairs


The Changing Face of Medical Affairs

MA is set to become a fully-fledged strategic partner. But what has driven this change & what can we expect in years to come?

By: Deirdre Coleman on Nov 22, 2016, originally posted here: https://social.eyeforpharma.com/clinical/changing-face-medical-affairs

The remarkable surge in the size and importance of the Medical Affairs function within pharma companies has roots going back decades. Over many years, pressure from regulatory agencies, payers and healthcare professionals, as well as public sentiment, has led to a clearer separation between the Medical and Commercial functions. It was between these separating tectonic plates that Medical Affairs emerged.

As the traditional single-customer pharma engagement model is replaced by a village of interconnected stakeholders, Medical Affairs is uniquely placed to engage with them. It is equipped to understand the challenges pharma’s stakeholders face and to work as a genuine partner to find solutions, improving patient care and creating value for all stakeholders.

“We are now looking at the medical community as an ongoing strategic investment, a long-term, mutually beneficial partnership, whereas before it was more transactional, more sporadic,” says Keith Allan, former Medical Director at Novartis. “The customer base is far broader now, with payers and regulators looking for evidence of the medical, clinical and economic value of our medicines. The needs of the medical community has expanded enormously, together with the technical complexity associated with the interactions. The [Medical Affairs] function is more strategic as we act as ambassadors and facilitators of information exchange, delivering insights back into Development. It calls for a broader set of capabilities, more business acumen and greater alignment with the commercial goals of the company.”

“Companies have to become the trusted scientific partner. Earning that trust comes through the science, not just pumping out commercial messages. If we’re not able to do this well, we will struggle. “

For Michael Zaiac, Head of Medical Affairs at Celgene, it is long-term engagement within a therapeutic area that builds and maintains long-term strategic partnerships with key opinion leaders. “To move from transaction to true partnership, you need to be in it for the long haul,” he says. “We develop a 15-year plan for what we’re going to do in each therapeutic area. We listen to HCPs and interpret what they want and produce items in partnership with them. We have to understand what our partners want to hear and generate the information they want to hear. We are the mediators – we are there to work with people”.

Critical capabilities

An expansion of capabilities is required if companies are to understand the patient experience, access, and influence a broad array of external healthcare stakeholders, and act as a liaison between the medical community and the internal research organization.

Medical Affairs teams need a wide range of capabilities, says Danie Du Plessis, Head of Medical Affairs at GlaxoSmithKline. “As part of our new business model, which puts Medical staff increasingly at the forefront of HCP interactions, we have emphasized four areas of medical competency and capability: scientific and product expertise, value and access, governance, and communications skills. We really recognize the need to bring those areas together into the ability to translate information into value – to be an engaging communicator, able to moderate and facilitate a conversation between peers with credibility and balance – a considerable skill in itself. They also need to have business acumen, understanding commercially what we need to do and translating the scientific data in a strategic way that would genuinely improve outcomes for patients,” he says.

However, the critical capability is a deep scientific knowledge in order to address unmet need and advance the treatment of the disease, says Gundula Schneidewind, VP, Medical Affairs, Europe and Canada at Takeda. ““In particular, this is true for specialty treatment; companies have to become the trusted scientific partner, earning that trust through the science not by pumping out messages. We owe it to the patients to generate knowledge and, in collaboration with external partners, help advance science.” This starts with deep therapeutic insight, including a better understanding of the epidemiology across geographies right through to data generation, she says. “Starting by recognizing unmet needs and working towards patient-centric solutions, companies can find ways to provide genuine value to those we serve. It’s our job to spread this top-notch knowledge and make it available to the wider community of treating physicians.”

The Trends Driving the Growth of Medical Affairs:

Physicians seeking peer-peer interaction; Physicians requesting greater scientific and evidence driven dialogue information on innovative medicines from industry; conventional commercial interactions are decreasing; customer-facing model is becoming increasingly ‘medicalized’

Tougher regulatory controls; societal expectation; Impacting relationships with HCPs & HCOs, with public scrutiny. Harsher compliance measures, with complex changing guidance, regulations & laws that differs between countries & carries risk of harming reputations through heterogeneity of approaches & leading to severe fiscal penalties

Increased transparency expectations; Rapidly emerging world-wide regulations demanding greater transparency on data from trials, publications, data disclosure, HCP financial transparency, non-HCP interactions, oversight of patient engagement

Increasing safety concerns; Growing concern about safety of medicines and requirement to increase the early signal detection, the speed of response on safety issues, utilization of big data approaches to better understand benefit-risk and encompassing social media as a source of safety information

Rising development costs; Impacting time & ability to deliver locally relevant evidence in a timely and cost-effective manner; increasing pressure on medical plans for local data. Adaptive licensing will require new approaches including need to innovate more early on for efficient in Life Cycle Management

Greater requirements for post- marketing evidence; Most approvals accompanied by Post-Marketing Surveillance and Risk Management Plan requirements. Creating capabilities and focus on developing and executing low-cost efficient observational studies is an imperative

Payors pushing for Real World Evidence; There is a rapid shift towards the requirement of community-based local evidence and higher hurdles for proving product value and defining relevant patient outcomes. In parallel with the increased availability of local data on outcomes and big-data analyzing capability, the shift towards mastering RWE is fundamental

Vocal patient populations; Influence of patients is fundamentally changing, with increased empowerment and social media rise of “consumerism”. Impact of Influential POLs blogging on trials & products, rapidly forming patient advocacy groups, alter perception of marketed drugs. Patient groups could also become critical sources of development /medical funding, and providing insights into shaping programs and educational needs

Shifting global demographics; Understanding heath care systems in rapidly developing countries will be essential to ensure the medicines can fit into the new system and ethnography. Building the evidence into the development programs will be challenging. Medical teams will need to address gaps and have local capabilities to execute studies

Source: Sanofi Medical Affairs Roadmap Presentation

The future for medical affairs

Medical Affairs has to become more proactive about bringing insights from a broader range of external medical decision-makers and influencers into early clinical development. Furthermore, it must also take a lead in demonstrating improved comparative efficacy and cost-effectiveness to payors by employing the real-world evidence and data generated by others. At the same time, it is important for Medical Affairs to re-establish pharmaceuticals’ integrity and credibility by communicating higher quality medical information that is of the highest relevance to customers. The time is right for Medical Affairs organizations to earn their place at the leadership table by creating opportunities to deliver new value for both patients and the healthcare ecosystem.

Nicola Smith, Regional Head of Operations, Field Medical Affairs at QuintilesIMS emphasizes the scope that exists for MA to add huge value to the development and commercial teams. “Their strength lies in their ability to gather insight and to help the organization understand how this information can be translated into strategy and value for stakeholders, the greater the level of actionable insights from the medical affairs teams, the better for everyone. Where could the function go? A long way. MA needs to stand up strongly for its strengths in and around the translation of research evidence into clinical practice in a compliant environment, with strong communication and scientific engagement which, like any scientific method, is listening, iterating, testing, and is flexible to both internal and external stakeholders, while meeting all the regulations. MA needs to strengthen its reach back into clinical development starting at the planning stage and be critically involved. It needs to reach in an appropriate way into the commercial organization – giving advice and inputting into the plan. Who knows the patient pathway better than MA? Is it the answer to every question? Absolutely not and there needs to be mutual respect of other team members including marketing, market access, clinical therapy teams and of the need to work together as a team. The challenge in the future will be maintaining a strong external focus, listening to the prescribers and taking that insight back into the organization to guide future strategy and future development”.

A fundamental challenge going forward will be to ensure that medical affairs as the public face of the organization is seen as a strategic leading partner with external and internal stakeholders, according to Antonio Tataranni, SVP, Head of Medical Affairs, Sanofi. “It means a number of things. MA need to have the right attitude – after all, what brought us here won’t get us there. It’s about taking ownership and leading certain strategic decisions. It’s crucial that we commit to providing the right data at the right time, moving from clinical trials increasingly into the Real World Evidence sphere – we need to own that. The future that we can create as an innovating function is largely dependent on talent and anticipating future needs, identifying knowledge gaps and filling them. I am profoundly convinced that the MA function needs to evolve with a constant reassessment that the offer matches the needs of the marketplace”.

This article is extracted from Trends in Medical Affairs. To download the magazine, click here.

Want to learn more about the many faces of Medical Affairs?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.